We are a privately held, clinical stage pharmaceutical company that develops novel, “best-in-class” oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.